Ann-Hunter Van Kirk is a Senior Equity Research Analyst at Bloomberg Intelligence covering the biopharmaceutical sector with a focus on gene editors and RNAi companies. A.H. brings a long career of sell-side healthcare equity research experience from prior positions at Barclays, BMO Capital Markets, and Cantor Fitzgerald. Ms. Van Kirk holds a master's degree from the London School of Economics and two bachelor's degrees from Southern Methodist University with honors.